# Anti-αIIbβ3 Immunization in Glanzmann Thrombasthenia: Prevalence and Associated Risk Factors: Thrombasthenia Anti-αIIbβ3 Antibodies Study (TAAS)

> **NCT04595617** · NA · COMPLETED · sponsor: **University Hospital, Bordeaux** · enrollment: 28 (actual)

## Conditions studied

- Glanzmann Thrombasthenia

## Interventions

- **BIOLOGICAL:** Antibodies screening

## Key facts

- **NCT ID:** NCT04595617
- **Lead sponsor:** University Hospital, Bordeaux
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-06
- **Primary completion:** 2023-07-06
- **Final completion:** 2023-07-06
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2024-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04595617

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04595617, "Anti-αIIbβ3 Immunization in Glanzmann Thrombasthenia: Prevalence and Associated Risk Factors: Thrombasthenia Anti-αIIbβ3 Antibodies Study (TAAS)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04595617. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*